Trial Profile
A Study of BYL719 in Adult Patients With Advanced Solid Malignancies.
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 27 Mar 2019
Price :
$35
*
At a glance
- Drugs Alpelisib (Primary)
- Indications Solid tumours
- Focus Adverse reactions
- Sponsors Novartis; Novartis Pharmaceuticals
- 01 Mar 2019 Results published in the Cancer Science
- 12 Sep 2017 Results assessing food effect on pharmacokinetics of alpelisib and prliminary effecacy (n=33) presented at the 42nd European Society for Medical Oncology Congress
- 26 Jan 2016 Status changed from recruiting to completed as reported by ClinicalTrials.gov.